PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07K 14/01, 16/08, G01N 33/68, A61P 31/20 — A1

(11) International Publication Number: WO 00/66621

(43) International Publication Date: 9 November 2000 (09.11.00)

(21) International Application Number: PCT/EP00/03958

(22) International Filing Date: 3 May 2000 (03.05.00)

(30) Priority Data:
9901601-6 4 May 1999 (04.05.99) SE

(71) Applicant *(for all designated States except US)*: TRIPEP AB [SE/SE]; Hälsovägen 7, S-141 57 Huddinge (SE).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: SÄLLBERG, Matti [SE/SE]; Stora Rönnens Gränd 15, S-181 68 Täby (SE).

(74) Agents: NILSSON, Brita et al.; AB Stockholms Patentbyrå, Zacco & Bruhn, P.O. Box 23101, S-104 35 Stockholm (SE).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PEPTIDES FROM THE TT VIRUS SEQUENCE AND MONOSPECIFIC ANTIBODIES BINDING TO THE TT VIRUS

(57) Abstract

The peptide having the amino acid sequence SEQ ID NO:1, and optionally this peptide in mixture with one or more peptides SEQ ID NO:3 – 11, is described. All these peptides correspond to regions of the genomic TT virus sequence. Further, monospecific antibodies binding to the TT virus are disclosed. The peptides may be coupled to a carrier and/or label, or immobilized on a solid phase. The peptide or peptide mixture, or the monospecific antibody may be used in a medicament or in diagnostic kits. The peptide or peptide mixture may also be used for immunization of a non-human mammal to produce monospecific antibodies directed against TT virus.